Wealth Enhancement Advisory Services LLC Trims Stock Holdings in CVS Health Corporation (NYSE:CVS)

Wealth Enhancement Advisory Services LLC cut its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 48.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 149,247 shares of the pharmacy operator's stock after selling 137,743 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in CVS Health were worth $10,111,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. LaFleur & Godfrey LLC grew its stake in CVS Health by 49.9% in the fourth quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator's stock valued at $217,000 after purchasing an additional 1,610 shares in the last quarter. TCW Group Inc. grew its position in shares of CVS Health by 2.5% in the 4th quarter. TCW Group Inc. now owns 17,601 shares of the pharmacy operator's stock valued at $790,000 after acquiring an additional 435 shares during the period. Wealthspire Advisors LLC increased its stake in shares of CVS Health by 10.1% during the 4th quarter. Wealthspire Advisors LLC now owns 15,962 shares of the pharmacy operator's stock worth $717,000 after purchasing an additional 1,468 shares during the last quarter. Howard Capital Management Inc. grew its holdings in CVS Health by 13.6% during the fourth quarter. Howard Capital Management Inc. now owns 13,846 shares of the pharmacy operator's stock worth $622,000 after purchasing an additional 1,653 shares during the period. Finally, B&D White Capital Company LLC bought a new stake in CVS Health in the fourth quarter valued at approximately $417,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CVS Health

In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of the firm's stock in a transaction dated Thursday, June 5th. The stock was purchased at an average cost of $63.70 per share, with a total value of $100,009.00. Following the transaction, the director now directly owns 12,007 shares in the company, valued at $764,845.90. This trade represents a 15.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.22% of the stock is owned by insiders.

Analyst Ratings Changes

CVS has been the subject of several research reports. Barclays set a $79.00 price target on CVS Health and gave the company an "overweight" rating in a report on Monday, June 2nd. UBS Group increased their target price on shares of CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research report on Friday, May 2nd. Robert W. Baird increased their price target on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. Cowen reiterated a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Finally, Royal Bank Of Canada boosted their price target on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research note on Monday, May 5th. Two research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, CVS Health currently has an average rating of "Moderate Buy" and an average target price of $74.75.

CVS Health Stock Up 1.3%

CVS traded up $0.84 during midday trading on Tuesday, hitting $67.65. The company had a trading volume of 7,567,565 shares, compared to its average volume of 10,904,511. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77. The stock's 50 day moving average price is $64.88 and its 200 day moving average price is $60.53. The company has a market capitalization of $85.58 billion, a price-to-earnings ratio of 16.15, a PEG ratio of 0.95 and a beta of 0.56. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The business had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter last year, the firm posted $1.31 EPS. CVS Health's revenue was up 7.0% compared to the same quarter last year. On average, research analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.